Survey on the prevention and incidence of haemolytic disease of the newborn in Italy

Blood Transfusion

Volumn 11, Issue 4, 2013, Pages 518-527

  Bennardello, Francesco ^a   Curciarello, Giuseppe ^b  

^a Servizio di Immunoematologia e Medicina Trasfusionale   (Italy)

^b SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

Anti D immunoglobulins; Anti D immunoprophylaxis; FMH; Haemolytic disease of the newborn

Indexed keywords

RHESUS D ANTIBODY;

ADULT; ARTICLE; BLEEDING; DRUG MEGADOSE; ERYTHROCYTE; EXCHANGE BLOOD TRANSFUSION; FEMALE; HEALTH SURVEY; HEMOLYTIC ANEMIA; HUMAN; IMMUNOPROPHYLAXIS; INCIDENCE; INTRAUTERINE BLOOD TRANSFUSION; ITALY; MAJOR CLINICAL STUDY; NEWBORN; PREGNANCY; QUESTIONNAIRE;

BLOOD TRANSFUSION, INTRAUTERINE; ERYTHROBLASTOSIS, FETAL; FEMALE; HUMANS; INCIDENCE; INFANT, NEWBORN; ITALY; MALE; PLASMA EXCHANGE; QUESTIONNAIRES; RHO(D) IMMUNE GLOBULIN;

EID: 84891936417     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.0179-12     Document Type: Article

References (40)

1. Mollison PL, Walker W. Controlled trials of the treatment of haemolytic disease of the newborn. Lancet 1952; i: 429-33.
2. Woodrow JC, Donohoe WT. Rh-immunization by pregnancy: results of a survey and their relevance to prophylactic therapy. Br Med J 1968; 4: 139-44.
3. Sansone G. La malattia emolitica neonatale, ieri e oggi. In: Sansone G, Dambrosio F (editors). Atti del Convegno sui Problemi Attuali della MEN, 1971: Genoa: Stringa Editore; 1971. p 17-26.
4. Tovey LA. Towards the conquest of Rh haemolytic disease: Britain's contribution and the role of serendipity. Transfus Med 1992; 2: 99-109.
5. Huchet, J, Dallemagne, S, Huchet, et al. Ante-partum administration of preventive treatment of Rh-D immunisation in rhesus-negative women. Parallel evaluation of transplacental passage of fetal blood cells. Results of a multicentre study carried out in the Paris region. J Gynecol Obstet Biol Reprod 1987; 16: 101-11.
6. MacKenzie IZ, Bowell P, Gregory H, et al. Routine antenatal rhesus D immunoglobulin prophylaxis: the results of a prospective 10 year study. Br J Obstet Gynaecol 1999; 106: 492-7.
7. Mayne S, Parker JH, Harden TA, et al. Rate of RhD sensitisation before and after implementation of a community based antenatal prophylaxis programme. Br Med J 1997; 315: 1588.
8. Tovey LA, Townley A, Stevenson BJ, Taverner J. The Yorkshire antenatal anti-D trial in primigravidae. Lancet 1983; 2: 244-6.
9. Chilcott J, Lloyd Jones M, Wight J, et al. A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are Rhesus-negative. Health Technol Assess 2003; 7: iii-62.
10. Turner RM, Lloyd-Jones M, Anumba DOC, et al. Routine antenatal anti-D prophylaxis in women who are Rh(D) negative: meta-analyses adjusted for differences in study design and quality. PLoS ONE 2012; 7: e30711.
11. Reali G. Forty years of anti-D immunoprophylaxis. Blood Transfus 2007; 5: 3-6.
12. Bowman JM. Alloimmune Hemolytic Disease of the Fetus and Newborn (Erythroblastosis Fetalis): Diagnosis, Management, and Prevention. GLOWM 2008; DOI 10.3843/GLOWM.10201.
13. Fung Kee Fung K, Eason E; SOGC Maternal-Fetal Medicine Committee; SOGC Genetics Committee. Prevention of Rh alloimmunization. SOGC Clinical Practice Guidelines, No. 133, September 2003. J Obstet Gynaecol Can 2003; 25: 765-73.
14. Legge 21 ottobre 2005, n. 219. Nuova disciplina of the attività trasfusionali e della produzione nazionale di emoderivati. Gazzetta Ufficiale della Repubblica Italiana, n. 251, 27/10/2005.
15. Velati C. A survey of the current use of anti-D immunoprophylaxis and the incidence of haemolytic disease of the newborn in Italy. Blood Transfus 2007; 5: 7-14.
16. Biffoni F, D'Angiolino A, Massaro AL, et al. Recommendations for the management of haemolytic disease of the newborn. Blood Transfus 2006; 4: 237-50.
17. ISTAT: Demografia in cifre. Nati per sesso e provincia - Anno di iscrizione 2010. Available at: http://demo.istat.it/altridati/IscrittiNascita/ 2010/T1.13.pdf. Accessed on: 06/04/2012.
18. Wagner FF, Frohmajer A, Flegel WA. RHD positive haplotypes in D negative Europeans. BMC Genet 2001; 2: 10.
19. Perrone AO, Mazzei C. The Rhesus system: new insights with particular reference to weak D phenotypes Blood Transfus 2003; 4: 299-313.
20. Sebring ES, Polensky HF. Detection of fetal-maternal hemorrhage in Rh immune globulin candidates. A rosetting technique using enzyme-treated Rh2Rh2 indicator erythrocytes. Transfusion 1982; 22: 468-71.
21. Moise KJ. Red blood cell alloimmunisation in pregnancy. Semin Hematolol 2005; 42: 169-78.
22. British Committee for Standards in Haematology (BCSH - a). Guidelines for the estimation of fetomaternal haemorrhage. Transfus Med 1999; 9: 87-92.
23. Pilgrim H, Lloyd-Jones M, Rees A. Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation. Health Technol Assess 2009; 13: iii, ix-xi, 1-103.
24. Royal College of Physicians of Edinburgh and Royal College of Obstetricians and Gynaecologist of UK, London. Statement from the Consensus Conference on anti-D prophilaxis. Vox Sang 1998; 74: 127-8.
25. Liumbruno GM, D'Alessandro A, Rea F, et al. The role of antenatal immunoprophylaxis in the prevention of maternal-foetal anti-Rh(D) alloimmunisation. Blood Transfus 2010; 8: 8-16.
26. Davies J, Chant R, Simpson S, Powell R. Routine antenatal anti-D prophylaxis - is the protection adequate? Transfus Med 2011; 21: 421-6.
27. National Institute for Health and Clinical Excellence (NICE). Routine antenatal anti-D prophylaxis for women who are Rhesus D negative. Available at: http://www.nice.org.uk/nicemedia/pdf/TA156Guidance.pdf. Accessed on 20/04/2013.
28. Royal College of Obstetricians and Gynaecologists (revised in May 2002). Clinical green top guidelines: - Use of anti-D immunoglobulin for Rh prophylaxis. Available at: http://www.neonatalformulary.com/pdfs/uk-guidelines/ RHESUS(D)IMMUNOGLOBULIN-RCOG-guideline.pdf. Accessed on 20/04/2013.
29. Flegel WA, Wagner FF. Molecular biology of partial D and weak D: implications for blood bank practice. J Clin Lab 2002; 48: 53-9.
30. British Committee for Standards in Haematology (BCSH). Guidelines for blood grouping and red cell antibody testing during pregnancy. Transfus Med 1996; 6: 71-4.
31. Royal College of Obstetricians and Gynaecologists. Clinical green top guidelines: the Use of anti-D immunoglobulin for Rh prophylaxis (revised March 2011) Available at: http://www.rcog.org.uk/files/rcog-corp/GTG22AntiD.pdf. Accessed on 20/04/2013.
32. Flegel WA. Molecular genetics and clinical applications for RH. Transfus Apher Sci 2011; 44: 81-91.
33. Lo YM. Fetal DNA in maternal plasma. Ann N Y Acad Sci 2000; 906: 141-7.
34. Lo YMD, Hjelm NM, Fidler C, et al. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med 1998; 339: 1734-8.
35. Wright C. Cell-free fetal nucleic acids for non-invasive prenatal diagnosis. Report of the UK expert working group. Cambridge PHG Foundation; 2009. Available at: http://www.phgfoundation.org/reports/4985/. Accessed on 20/04/2012.
36. Finning K, Martin P, Daniels G. The use of maternal plasma for prenatal RhD blood group genotyping. Methods Mol Biol 2009; 496: 143-57.
37. Geifman-Holtzman O, Grotegut CA, Gaughan JP. Diagnostic accuracy of noninvasive fetal Rh genotyping from maternal blood - a meta-analysis. Am J Obstet Gynecol 2006; 195: 1163-73.
38. Daniels G, Finning K, Martin P, Summers J. Fetal RhD genotyping: a more efficient use of anti-D immunoglobulin. Transfus Clin Biol 2007; 14: 568-71.
39. Benachi A, Delahaye S, Leticee N, et al. Impact of non-invasive fetal RhD genotyping on management costs of rhesus-D negative patients: results of a French pilot study. Eur J Obstet Gynecol Reprod Biol 2012; 162: 28-32.
40. Finning K, Martin P, Summers J, Daniels G. Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal plasma. Transfusion 2007; 47: 2126-33.